CARsgen Therapeutics Widens Loss in 2024

MT Newswires Live

03-19

CARsgen Therapeutics (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.

Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.

Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.

The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2520974402"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520974402\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2520974402?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-19 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520974402","market":"nz","top_or_hot":-1,"title":"CARsgen Therapeutics Widens Loss in 2024","media":"MT Newswires Live","content":"<html><body><p> CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.</p><p>Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.</p><p>Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.</p><p>The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen Therapeutics Widens Loss in 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen Therapeutics Widens Loss in 2024\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-03-19 17:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.</p><p>Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.</p><p>Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.</p><p>The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科濟藥業-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520974402","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520974402","pubTimestamp":1742378094,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CARsgen Therapeutics  widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B","BK1587":"次新股","LENZ":"Therapeutics","BK1585":"昨日强势股","BK1161":"生物科技","BK4139":"生物科技","BK1574":"生物医药B类股"},"translate_title":"科济康治疗2024年亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":0.9,"LENZ":1},"content_text":"CARsgen Therapeutics (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}